Legislation introduced by Sen. Cotton on 28 July would, among other things, prohibit federal procurement of pharmaceutical products with active pharmaceutical ingredients produced in mainland China (to be phased in over two years) and require drug companies to list APIs and their countries of origin on the labels of imported and domestically-produced finished drug products. More